The National Institutes of Health is teaming with government, biopharmaceutical, life science and non-profit organizations to overcome obstacles and increase success for advancing promising treatments for Parkinson’s disease (PD). Part of the NIH Accelerating Medicines Partnership (AMP), AMP PD will focus on identifying and validating promising markers of disease called biomarkers that may be useful in tracking the progression of PD and could serve as biological targets for the development of new drugs.
“Advancing treatments for Parkinson’s disease is hampered by insufficient understanding of biological networks; drugs aimed at seemingly promising therapeutic targets fail in clinical trials,” said NIH Director Francis S. Collins, M.D., Ph.D. “By combining our expertise and resources, AMP PD partners hope to increase our collective odds of success in accelerating the development of effective treatments for a million Americans who suffer from this debilitating disease.”
Read the NIH press release: NIH launches partnership to improve success of clinical trials for patients with Parkinson’s disease